Targacept up on TC-5214 data

Targacept Inc. (NASDAQ:TRGT) was up $4.19 (137%) to $7.25 on Wednesday after announcing that its TC-5214 met all endpoints in a Phase IIb trial to treat major depressive disorder (MDD). In 265 patients who were partial- or non-responders to citalopram, TC-5214 plus citalopram met the primary endpoint of significantly improving the mean Hamilton Depression Rating (HAM-D) score from baseline compared with placebo plus citalopram (p<0.0001). TC-5214 also significantly improved the trial's secondary endpoints, including measures of depression, irritability, disability, cognition, severity of illness and global improvement. ...